These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 27112899)

  • 1. Dual role of LRRC8A-containing transporters on cisplatin resistance in human ovarian cancer cells.
    Sørensen BH; Dam CS; Stürup S; Lambert IH
    J Inorg Biochem; 2016 Jul; 160():287-95. PubMed ID: 27112899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downregulation of LRRC8A protects human ovarian and alveolar carcinoma cells against Cisplatin-induced expression of p53, MDM2, p21Waf1/Cip1, and Caspase-9/-3 activation.
    Sørensen BH; Nielsen D; Thorsteinsdottir UA; Hoffmann EK; Lambert IH
    Am J Physiol Cell Physiol; 2016 Jun; 310(11):C857-73. PubMed ID: 26984736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquired cisplatin resistance in human ovarian A2780 cancer cells correlates with shift in taurine homeostasis and ability to volume regulate.
    Sørensen BH; Thorsteinsdottir UA; Lambert IH
    Am J Physiol Cell Physiol; 2014 Dec; 307(12):C1071-80. PubMed ID: 25252947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-133a enhances the sensitivity of Hep-2 cells and vincristine-resistant Hep-2v cells to cisplatin by downregulating ATP7B expression.
    Wang X; Zhu W; Zhao X; Wang P
    Int J Mol Med; 2016 Jun; 37(6):1636-42. PubMed ID: 27121102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protolichesterinic Acid, Isolated from the Lichen Cetraria islandica, Reduces LRRC8A Expression and Volume-Sensitive Release of Organic Osmolytes in Human Lung Epithelial Cancer Cells.
    Thorsteinsdottir UA; Thorsteinsdottir M; Lambert IH
    Phytother Res; 2016 Jan; 30(1):97-104. PubMed ID: 26549524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 8‑bromo‑7‑methoxychrysin induces apoptosis by regulating Akt/FOXO3a pathway in cisplatin‑sensitive and resistant ovarian cancer cells.
    Ding Q; Chen Y; Zhang Q; Guo Y; Huang Z; Dai L; Cao S
    Mol Med Rep; 2015 Oct; 12(4):5100-8. PubMed ID: 26151347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Copper efflux transporter (ATP7B) contributes to the acquisition of cisplatin-resistance in human oral squamous cell lines.
    Yoshizawa K; Nozaki S; Kitahara H; Ohara T; Kato K; Kawashiri S; Yamamoto E
    Oncol Rep; 2007 Oct; 18(4):987-91. PubMed ID: 17786364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic Targeting of ATP7B in Ovarian Carcinoma.
    Mangala LS; Zuzel V; Schmandt R; Leshane ES; Halder JB; Armaiz-Pena GN; Spannuth WA; Tanaka T; Shahzad MM; Lin YG; Nick AM; Danes CG; Lee JW; Jennings NB; Vivas-Mejia PE; Wolf JK; Coleman RL; Siddik ZH; Lopez-Berestein G; Lutsenko S; Sood AK
    Clin Cancer Res; 2009 Jun; 15(11):3770-80. PubMed ID: 19470734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subunit composition of VRAC channels determines substrate specificity and cellular resistance to Pt-based anti-cancer drugs.
    Planells-Cases R; Lutter D; Guyader C; Gerhards NM; Ullrich F; Elger DA; Kucukosmanoglu A; Xu G; Voss FK; Reincke SM; Stauber T; Blomen VA; Vis DJ; Wessels LF; Brummelkamp TR; Borst P; Rottenberg S; Jentsch TJ
    EMBO J; 2015 Dec; 34(24):2993-3008. PubMed ID: 26530471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular pharmacology of cisplatin in relation to the expression of human copper transporter CTR1 in different pairs of cisplatin-sensitive and -resistant cells.
    Beretta GL; Gatti L; Tinelli S; Corna E; Colangelo D; Zunino F; Perego P
    Biochem Pharmacol; 2004 Jul; 68(2):283-91. PubMed ID: 15194000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells.
    Samimi G; Safaei R; Katano K; Holzer AK; Rochdi M; Tomioka M; Goodman M; Howell SB
    Clin Cancer Res; 2004 Jul; 10(14):4661-9. PubMed ID: 15269138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TTYH1 and TTYH2 Serve as LRRC8A-Independent Volume-Regulated Anion Channels in Cancer Cells.
    Bae Y; Kim A; Cho CH; Kim D; Jung HG; Kim SS; Yoo J; Park JY; Hwang EM
    Cells; 2019 Jun; 8(6):. PubMed ID: 31181821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Berberine Sensitizes Human Ovarian Cancer Cells to Cisplatin Through miR-93/PTEN/Akt Signaling Pathway.
    Chen Q; Qin R; Fang Y; Li H
    Cell Physiol Biochem; 2015; 36(3):956-65. PubMed ID: 26087719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells.
    Kalayda GV; Wagner CH; Buss I; Reedijk J; Jaehde U
    BMC Cancer; 2008 Jun; 8():175. PubMed ID: 18565219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular composition and heterogeneity of the LRRC8-containing swelling-activated osmolyte channels in primary rat astrocytes.
    Schober AL; Wilson CS; Mongin AA
    J Physiol; 2017 Nov; 595(22):6939-6951. PubMed ID: 28833202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of volume-regulated and calcium-activated anion channels in cell volume homeostasis, cancer and drug resistance.
    Hoffmann EK; Sørensen BH; Sauter DP; Lambert IH
    Channels (Austin); 2015; 9(6):380-96. PubMed ID: 26569161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression profile of copper transporters in sensitive and cisplatin/oxaliplatin-resistant tumor cell lines.
    Kassack MU; Stratenschulte C
    Int J Clin Pharmacol Ther; 2005 Dec; 43(12):597-8. PubMed ID: 16372532
    [No Abstract]   [Full Text] [Related]  

  • 18. Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters.
    Samimi G; Howell SB
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):781-8. PubMed ID: 16170571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Annexin A4-conferred platinum resistance is mediated by the copper transporter ATP7A.
    Matsuzaki S; Enomoto T; Serada S; Yoshino K; Nagamori S; Morimoto A; Yokoyama T; Kim A; Kimura T; Ueda Y; Fujita M; Fujimoto M; Kanai Y; Kimura T; Naka T
    Int J Cancer; 2014 Apr; 134(8):1796-809. PubMed ID: 24150977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin sensitivity of oral squamous carcinoma cells is regulated by Na+,K+-ATPase activity rather than copper-transporting P-type ATPases, ATP7A and ATP7B.
    Ahmed Z; Deyama Y; Yoshimura Y; Suzuki K
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):643-50. PubMed ID: 18545997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.